UBS Group Reiterates “GBX 9,200” Price Target for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN) has been given a GBX 9,200 ($120.20) price objective by equities researchers at UBS Group in a research note issued to investors on Wednesday, Borsen Zeitung reports. UBS Group’s price target would indicate a potential upside of 13.20% from the company’s current price.

Several other equities research analysts also recently issued reports on the company. JPMorgan Chase & Co. set a £100 ($130.65) price target on AstraZeneca in a research report on Wednesday. Barclays reaffirmed an “overweight” rating and issued a £100 ($130.65) price target on shares of AstraZeneca in a research report on Monday, July 19th. Morgan Stanley reaffirmed an “overweight” rating and issued a GBX 9,800 ($128.04) price target on shares of AstraZeneca in a research report on Monday, August 9th. The Goldman Sachs Group set a GBX 6,950 ($90.80) price target on AstraZeneca in a research report on Monday, August 9th. Finally, Berenberg Bank decreased their target price on AstraZeneca from £100 ($130.65) to GBX 9,500 ($124.12) and set a “buy” rating on the stock in a research report on Wednesday, September 1st. Two investment analysts have rated the stock with a sell rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of GBX 9,401.67 ($122.83).

LON AZN opened at GBX 8,127 ($106.18) on Wednesday. The firm has a market cap of £125.90 billion and a P/E ratio of 39.19. The stock’s 50-day moving average is GBX 8,434.84 and its two-hundred day moving average is GBX 7,961.27. AstraZeneca has a fifty-two week low of GBX 6,736 ($88.01) and a fifty-two week high of GBX 8,848 ($115.60). The company has a debt-to-equity ratio of 190.47, a current ratio of 1.23 and a quick ratio of 1.01.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.

Recommended Story: Growth Stocks

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.